Figure 3. The influence of insert position and somatic mutations on antibody specificity.

a, Schematic representation of LAIR1-containing antibodies produced by different insertion modalities. b, Scheme of the constructs (C1-C10) containing LAIR1 or other Ig-like domains in different positions which were tested for binding to a set of antigens or anti-domain antibodies by ELISA or FACS. The construct domains and their binding values to the cognate ligands are color coded as depicted in the figure. The V and J segments that do not contribute to any binding are not colored. BKC3, in grey, is a negative control. LAIR1^D21, LAIR1^M1 and LAIR1^J5 are the exons from MGD21, MGM1 and MGJ5 antibodies. LAIR1^gen is the unmutated genomic sequence of LAIR1 encoded on chromosome 19. MGD^UCA = unmutated common ancestor of donor D antibodies; GL = germline. Data are from one experiment out of two. c, Binding of LAIR1-containing antibodies to erythrocytes infected with nine parasite isolates and to human collagen (n=1). Values refer to binding at a concentration of 1 μg ml^-1. The MGD^UCA was also tested at 100 μg ml^-1. The number of amino acid substitutions is reported in brackets next to the antibody names.